Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase NA 1Phase 4 1Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 5Uterine Cervical Neoplasms 4Stomach Neoplasms 3Neoplasms 3Lung Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Pancreatic Intraductal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Thrombosis 1Stage IA Uterine Sarcoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor Cancer 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Peripheral Nervous System Diseases 1Pancreatic Cyst 1Pain 1Organoid 1Neoplasms, Germ Cell and Embryonal 1NSCLC 1Motor Activity 1Medulloblastoma 1Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer 1

Interventions

tivozanib 1temsirolimus 1Whey Proteins 1Sunitinib 1Paclitaxel 1Nutrition Assessment 1Crizotinib 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Solid Tumors × Paclitaxel × Clear all
NCT01369433 2020-09-01

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

AVEO Pharmaceuticals, Inc.

Phase NA Terminated
225 enrolled 7 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡